The discovery of immune checkpoints and subsequent clinical development of ICIs, particularly mAbs targeting PD‐1, have revolutionised the field of oncology, providing patients with difficult‐to‐treat cancers much needed immunotherapy options. Here, PDCD1 is linked to cancer.